CliffBio
small molecule

METHYLENE BLUE

METHYLENE BLUE

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameMETHYLENE BLUE
Active ingredientMETHYLENE BLUE
Strength50MG/10ML (5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2024
Marketing statusRX

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

METHYLENE BLUE patent cliff — loss of exclusivity — | CliffBio